"ассылочки" говорят об обратном: первичная профилактика аспирином не предупреждает СССмертность, а каждый предупрежденный кардиоваскулярный эпизод или ИМ достигается примерно за счет 2 кровотечений:
Our objective was to assess the impact (and safety) of aspirin on vascular and nonvascular outcomes in primary prevention.
RESULTS: During a mean (SD) follow-up of 6.0 (2.1) years involving over 100, 000 participants, aspirin treatment reduced total CVD events by 10% (OR, 0.90; 95% CI, 0.85-0.96; number needed to treat, 120), driven primarily by reduction in nonfatal MI (OR, 0.80; 95% CI, 0.67-0.96; number needed to treat, 162). There was no significant reduction in CVD death (OR, 0.99; 95% CI, 0.85-1.15) or cancer mortality (OR, 0.93; 95% CI, 0.84-1.03), and there was increased risk of nontrivial bleeding events (OR, 1.31; 95% CI, 1.14-1.50; number needed to harm, 73).
CONCLUSIONS: Despite important reductions in nonfatal MI, aspirin prophylaxis in people without prior CVD does not lead to reductions in either cardiovascular death or cancer mortality. Because the benefits are further offset by clinically important bleeding events, routine use of aspirin for primary prevention is not warranted and treatment decisions need to be considered on a case-by-case basis.
Arch Intern Med. 2012 Feb 13;172(3):209-16. Epub 2012 Jan 9.
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.
|